Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Optimizing processing conditions to achieve a critical quality attribute (CQA) is an integral part of pharmaceutical quality by design (QbD). It identifies combinations of material and processing parameters ensuring that processing conditions achieve a targeted CQA. Optimum processing conditions are formulation and equipment-dependent. Therefore, it is challenging to translate a process design between formulations, pilot-scale and production-scale equipment. In this study, an empirical model was developed to determine optimum processing conditions for direct compression formulations with varying flow properties, across pilot- and production-scale tablet presses. The CQA of interest was tablet weight variability, expressed as percentage relative standard deviation. An experimental design was executed for three model placebo blends with varying flow properties. These blends were compacted on one pilot-scale and two production-scale presses. The process model developed enabled the optimization of processing parameters for each formulation, on each press, with respect to a target tablet weight variability of <1%RSD. The model developed was successfully validated using data for additional placebo and active formulations. Validation formulations were benchmarked to formulations used for model development, employing permeability index values to indicate blend flow.

Details

Title
Process Model Approach to Predict Tablet Weight Variability for Direct Compression Formulations at Pilot and Production Scale
Author
Peddapatla, Raghu V G 1   VIAFID ORCID Logo  ; Sheridan, Gerard 2 ; Slevin, Conor 2 ; Swaminathan, Shrikant 3 ; Browning, Ivan 4 ; Clare O’Reilly 4 ; Worku, Zelalem A 4 ; Egan, David 5 ; Sheehan, Stephen 4 ; Crean, Abina M 6 

 SSPC Pharmaceutical Research Centre, School of Pharmacy, University College Cork, T12 K8AF Cork, Ireland; [email protected] (R.V.G.P.); [email protected] (A.M.C.); Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; [email protected] (G.S.); [email protected] (C.S.); [email protected] (I.B.); [email protected] (C.O.); [email protected] (Z.A.W.) 
 Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; [email protected] (G.S.); [email protected] (C.S.); [email protected] (I.B.); [email protected] (C.O.); [email protected] (Z.A.W.); Pharmaceutical Manufacturing Technology Centre (PMTC), Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland; [email protected] 
 Alkermes Inc., Waltham, MA 02451, USA; [email protected] 
 Alkermes Pharma Ireland Limited, N37 EA09 Athlone, Ireland; [email protected] (G.S.); [email protected] (C.S.); [email protected] (I.B.); [email protected] (C.O.); [email protected] (Z.A.W.) 
 Pharmaceutical Manufacturing Technology Centre (PMTC), Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland; [email protected] 
 SSPC Pharmaceutical Research Centre, School of Pharmacy, University College Cork, T12 K8AF Cork, Ireland; [email protected] (R.V.G.P.); [email protected] (A.M.C.) 
First page
1033
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
19994923
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2554679215
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.